Research & Development

We are actively driving research and development globally with partnerships specializing in the fields of interest. Our focus is to develop botanical based pharmaceutical medicine for in-market use globally

Psilocybin

• Phase II Clinical Trial approved March 2022 in South Africa for the use of Psilocybin API for the treatment of Major Depressive Disorder
• Psilocybin cultivation research and development application submitted in South Africa on current 23 hectare property

Cannabidiol (CBD) for the treatment of Traumatic Brain Injury

Cannabidiol (CBD) for the treatment of Traumatic Brain Injury

• Utilizing CBD API for the treatment of TBI in sports related head injuries
• Phase 1 Clinical Trial submission expected Q3 2022 with commencement late 2022

Cannabidiol (CBD) for the treatment Schizophrenia

• Utilizing CBD API in combination with other treatments in the reduction of relapse schizophrenia
• Phase 1 Clinical Trial submission expected Q3 2022 with commencement in 2023

Scroll to Top